Further, there are patients with “BRCA mutated-like” ovarian carcinomas and impaired HR (i.e: with amplification/overexpression of EMSY [44, 45]; with structural variances/hypermethylation in BRCA1/2 [46, 47] and with mutation in genes involved in HR [5, 48]). Here, BRCA1 is linked to ovarian carcinoma.